Study Complete
Sponsor ID
20030207

A Study of Darbepoetin Alfa in Anemic Subjects with Low Risk Myelodysplastic Syndrome

Sponsor ID
20030207
Clinicaltrials.gov ID
NCT00095264
EUCTIS ID
N/A
EudraCT ID
N/A

Study Details

The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).

Additional Study Details

Phase
Phase 2
Product
darbepoetin alfa
Type
Interventional
Masking
None (Open Label)
Enrollment
209
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

No locations found.